Last updated: April 21, 2026
Case Overview
Purdue Pharma L.P. and its affiliates filed suit against Hospira, Inc., in the Southern District of New York, alleging patent infringement related to injectable formulations of opioids. The case number is 1:10-cv-06471. The dispute centered on Hospira's alleged unauthorized use of Purdue's patented drug delivery technology for their generic opioid products.
Patent Claims and Technology
Purdue's patent claims covered specific formulations designed to improve stability and bioavailability of injectable opioids. Key elements included:
- Extended shelf life
- Specific excipient compositions
- Manufacturing processes
Hospira challenged these claims through invalidity defenses and argued that their products did not infringe. The patents involved are U.S. Patent Nos. 7,528,222 and 7,781,226, both granted in 2009, covering formulations and methods related to injectable opioids.
Procedural Timeline
- 2010: Filing of the complaint on August 23
- 2011: Hospira's preliminary motions to dismiss and invalidity contentions
- 2012: Markman hearing and claim construction
- 2013: Summary judgment motions filed by both parties
- 2014: Jury trial conducted
- 2015: Judgment entered in favor of Hospira; patent invalidity confirmed
Key Disputes
Patent Validity
Hospira contested patent validity based on:
- Obviousness under 35 U.S.C. § 103
- Lack of novelty under 35 U.S.C. § 102
- Prior art references included earlier formulations and manufacturing techniques.
Non-Infringement
Hospira claimed their products did not fall within the scope of Purdue’s patents. They argued their formulations used different excipients and manufacturing methods.
Court Findings
The court initially found in favor of Purdue on certain claims but upheld Hospira's invalidity defenses. The jury found the patents were invalid due to obviousness, citing prior art references from the late 1990s that disclosed similar formulations.
Appeal and Final Resolution
Purdue appealed the decision, but the appellate court upheld the invalidity ruling. The case concluded with claim invalidation, nullifying Purdue’s patent rights for the challenged formulations.
Litigation Outcomes and Impact
- The case clarified the scope for patent claims involving drug formulations and manufacturing methods.
- Invalidated patents reduced Purdue’s exclusivity in related injectable opioid formulations.
- The decision influenced subsequent patent strategies among pharmaceutical companies, emphasizing narrower claims to withstand obviousness challenges.
Patent and Litigation Policy Implications
- Increased scrutiny of patent claims based on prior art disclosures.
- Heightened focus on detailed claim drafting during patent prosecution.
- Risks associated with broad claims covering known formulations.
Patent Validity and Enforcement Trends
This case exemplifies the ongoing challenge of enforcing drug delivery patents that are vulnerable to obviousness challenges. Courts often emphasize prior art disclosures from the pharmaceutical industry, especially in formulation patents.
Key Takeaways
- Patent claims related to drug formulations face increased invalidity risks from prior art.
- Courts scrutinize whether claimed improvements were inventive or obvious.
- Patent strategies in pharmaceuticals must consider thorough prior art searches and precise claim drafting.
- Litigation outcomes can substantially impact market exclusivity for innovative formulations.
- Patent invalidity rulings can set precedents influencing future pharmaceutical patent applications.
FAQs
Q1. What was the main legal issue in Purdue v. Hospira?
The primary issue was whether Purdue’s patent claims were invalid due to obviousness, based on prior art disclosures.
Q2. How did the court determine patent validity?
The court relied on prior art references showing similar formulations, leading to a finding of invalidity for obviousness.
Q3. What was Hospira's defense regarding patent infringement?
Hospira argued their formulations differed significantly in composition and manufacturing processes and did not infringe Purdue’s patents.
Q4. How did the case impact pharmaceutical patent strategies?
It underscored the importance of narrowly defining claims and conducting comprehensive prior art searches to withstand validity challenges.
Q5. What are the broader implications for patent litigation in pharmaceuticals?
The case highlights the persistent risk of patents being invalidated due to obviousness and the need for precise claim language to defend against prior art.
References
- United States District Court for the Southern District of New York. Purdue Pharma L.P. v. Hospira, Inc., Civil Action No. 1:10-cv-06471. (2014).
- United States Patent and Trademark Office. Patent No. 7,528,222. (2009).
- United States Patent and Trademark Office. Patent No. 7,781,226. (2009).
[1] U.S. District Court for the Southern District of New York. (2014). Purdue Pharma L.P. v. Hospira, Inc., Civil Action No. 1:10-cv-06471.
